Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (64) 64
Book / eBook (18) 18
Newspaper Article (10) 10
Web Resource (3) 3
Conference Proceeding (2) 2
Book Chapter (1) 1
Patent (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atrial fibrillation (16) 16
stroke (14) 14
humans (13) 13
index medicus (12) 12
warfarin (11) 11
aged (10) 10
female (10) 10
male (10) 10
dabigatran (9) 9
middle aged (9) 9
cardiac arrhythmia (8) 8
cardiovascular (8) 8
care and treatment (8) 8
abridged index medicus (7) 7
authors, french (7) 7
correspondence (7) 7
internal medicine (7) 7
stroke - prevention & control (7) 7
anticoagulants (6) 6
atrial fibrillation - complications (6) 6
gide, andré (6) 6
registries (6) 6
aged, 80 and over (5) 5
atrial fibrillation - drug therapy (5) 5
biography (5) 5
cardiac & cardiovascular systems (5) 5
dabigatran - therapeutic use (5) 5
environmental education (5) 5
fibrinolytic agents - therapeutic use (5) 5
gide, andré, 1869-1951 (5) 5
oral anticoagulation (5) 5
risk (5) 5
risk factors (5) 5
stroke - etiology (5) 5
therapy (5) 5
analysis (4) 4
anticoagulants - adverse effects (4) 4
anticoagulants - therapeutic use (4) 4
antithrombins - therapeutic use (4) 4
euro heart survey (4) 4
french literature (4) 4
lighting (4) 4
management (4) 4
medicine, general & internal (4) 4
patients (4) 4
prevention (4) 4
prospective studies (4) 4
stroke prevention (4) 4
treatment outcome (4) 4
1869-1951 (3) 3
adjustment (3) 3
adult (3) 3
age (3) 3
alcohol (3) 3
anticoagulation (3) 3
atrial-fibrillation (3) 3
cities (3) 3
councils (3) 3
cross-sectional studies (3) 3
design (3) 3
drug therapy (3) 3
education & educational research (3) 3
fibrillation (3) 3
hematology (3) 3
hypertension (3) 3
journal article (3) 3
newly marketed medications (3) 3
peripheral vascular disease (3) 3
pharmacology & pharmacy (3) 3
registry (3) 3
safety (3) 3
warfarin - adverse effects (3) 3
20th century (2) 2
adherence (2) 2
adolescent (2) 2
antithrombins (2) 2
atrial fibrillation - epidemiology (2) 2
authors (2) 2
benzimidazoles - adverse effects (2) 2
beta-alanine - analogs & derivatives (2) 2
cardiovascular disease (2) 2
care (2) 2
chads-vasc score (2) 2
children and adult learning (2) 2
christmas (2) 2
clinical trials (2) 2
clothing industry (2) 2
cohort studies (2) 2
criticism and interpretation (2) 2
dabigatran - adverse effects (2) 2
databases (2) 2
diabetes (2) 2
discontinuation (2) 2
drug administration schedule (2) 2
ecology (2) 2
environmental studies (2) 2
esc guidelines (2) 2
evaluation (2) 2
events (2) 2
fibrinolytic agents - adverse effects (2) 2
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
St. Michael's College (John M. Kelly) - 2nd Floor (8) 8
Robarts - Stacks (7) 7
UTL at Downsview - May be requested (7) 7
Victoria University E.J. Pratt - Stacks (5) 5
UofT at Scarborough - Stacks (2) 2
Music - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Victoria University E.J. Pratt - Storage (1) 1
Victoria University E.J. Pratt - Virginia Woolf (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
by Huisman, M.V and Rothman, K.J and Paquette, M and Teutsch, C and Diener, H.C and Dubner, S.J and Halperin, J.L and Ma, C.S and Zint, K and Elsaesser, A and Bartels, D.B and Lip, G.Y and Hemels, M.E and et al and GLORIA-AF Investigators
Journal of the American College of Cardiology, ISSN 0735-1097, 2017, Volume 69, Issue 7, pp. 777 - 785
BACKGROUND: GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry... 
registry | oral anticoagulation | atrial fibrillation | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | GUIDELINES | RISK | EUROPEAN-SOCIETY | ATRIAL-FIBRILLATION | ANTITHROMBOTIC TREATMENT | THERAPY | WARFARIN | ORAL ANTICOAGULANTS | Stroke - prevention & control | Prospective Studies | Cross-Sectional Studies | Antithrombins - therapeutic use | Humans | Middle Aged | Atrial Fibrillation - complications | Male | Dabigatran - therapeutic use | Stroke - etiology | Internationality | Fibrinolytic Agents - therapeutic use | Female | Registries | Aged | Hypertension | Heart failure | Cardiac arrhythmia | Anticoagulants | Stroke | Statistical analysis | Cardiovascular disease | Alcohol | Valves | Family medical history | Patients | Demographics | Onsite | Quality | Data collection | Trends | Clinical medicine | Diabetes | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II
by Huisman, Menno V., MD and Rothman, Kenneth J., DrPH and Paquette, Miney, MSc and Teutsch, Christine, MD and Diener, Hans Christoph, MD and Dubner, Sergio J., MD and Halperin, Jonathan L., MD and Ma, Changsheng, MD and Zint, Kristina, MD and Elsaesser, Amelie, MD and Bartels, Dorothee B., MD and Lip, Gregory Y.H., MD and GLORIA-AF Investigators
American Journal of Medicine, The, ISSN 0002-9343, 2015, Volume 128, Issue 12, pp. 1306 - 1313.e1
Abstract Background The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) was designed to provide... 
Internal Medicine | Stroke | Anticoagulation | Registry | Atrial fibrillation | MANAGEMENT | COUNTRIES | STROKE PREVENTION | ORAL ANTICOAGULATION | GUIDELINES | RISK | INTRACRANIAL HEMORRHAGE | MEDICINE, GENERAL & INTERNAL | WARFARIN | EURO HEART SURVEY | OUTCOMES | Dabigatran - adverse effects | Stroke - prevention & control | Prospective Studies | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Anticoagulants - therapeutic use | Male | Treatment Outcome | Anticoagulants - adverse effects | Dabigatran - therapeutic use | Fibrinolytic Agents - adverse effects | Practice Patterns, Physicians' - statistics & numerical data | Vitamin K - antagonists & inhibitors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Female | Registries | Aged | Aspirin - therapeutic use | Clinical trials | Medical colleges | Care and treatment | Pharmaceutical industry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation
by Paquette, Miney and Riou França, Lionel and Teutsch, Christine and Diener, Hans-Christoph and Lu, Shihai and Dubner, Sergio J and Ma, Chang Sheng and Rothman, Kenneth J and Zint, Kristina and Halperin, Jonathan L and Huisman, Menno V and Lip, Gregory Y.H and Nieuwlaat, Robby
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2017, Volume 70, Issue 13, pp. 1573 - 1583
Guidelines recommend long-term oral anticoagulation therapy for stroke prevention in patients with atrial fibrillation (AF). Treatment discontinuation rates in... 
non-VKA oral anticoagulant | oral anticoagulation | discontinuation | stroke prevention | vitamin K antagonist | STROKE | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTOR | WARFARIN | PATTERNS | ADHERENCE | Stroke - prevention & control | Drug Administration Schedule | Antithrombins - therapeutic use | Humans | Middle Aged | Atrial Fibrillation - complications | Male | Dabigatran - therapeutic use | Socioeconomic Factors | Medication Adherence | Stroke - etiology | Aged, 80 and over | Female | Aged | Cohort Studies | Care and treatment | Anticoagulants (Medicine) | Pharmaceutical industry | Atrial fibrillation | Prevention | Stroke (Disease) | Analysis | Hypertension | Heart | Anticoagulants | Cardiac arrhythmia | Therapy | Stroke | Thoracic surgery | Statistical analysis | Alcohol | Patients | Risk factors | Prescription drugs | Regression models | Fibrillation | Inhibitors | Cardiology | Drug dosages | Vitamin K
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Laguna Beach council says OK to Circle K to sell liquor
by Bradley Zint
10/2018
Low income groups | Councils | Liquor laws & regulations | Alcohol | Convenience stores | Sunday legislation
Web Resource
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry
by Huisman, Menno V and Rothman, Kenneth J and Paquette, Miney and Teutsch, Christine and Diener, Hans-Christoph and Dubner, Sergio J and Halperin, Jonathan L and Ma, Chang Sheng and Zint, Kristina and Elsaesser, Amelie and Lu, Shihai and Bartels, Dorothee B and Lip, Gregory Y.H and GLORIA-AF Investigators
American Heart Journal, ISSN 0002-8703, 04/2018, Volume 198, pp. 55 - 63
GLORIA-AF is a large, global, prospective registry program of newly diagnosed atrial fibrillation (AF) patients with ≥1 stroke risk factors. We describe the... 
CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | THERAPY | WARFARIN | SAFETY | CARE | Confidence Intervals | Prospective Studies | Age Factors | Follow-Up Studies | Humans | Middle Aged | Male | Dabigatran - therapeutic use | Time Factors | Aged, 80 and over | Female | Registries | Stroke - prevention & control | Drug Administration Schedule | Global Health | Risk Assessment | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Kaplan-Meier Estimate | Stroke - etiology | Atrial Fibrillation - diagnostic imaging | Internationality | Primary Prevention - methods | Sex Factors | Survival Analysis | Aged | Stroke (Disease) | Prevention | Care and treatment | Analysis | Atrial fibrillation | Myocardial infarction | Cardiac arrhythmia | Heart attacks | Physicians | Embolisms | Clinical trials | Cardiovascular disease | Dosage | Bleeding | Risk factors | Incidence | Training | Confidence intervals | Fibrillation | Ischemia | Safety | Age | Vitamin K | Heart failure | Hypertension | Anticoagulants | Cerebral infarction | Medical research | Stroke | Enrollments | Health risks | Risk analysis | Patients | Thrombosis | Family physicians | Coronary vessels | Infarction | Diabetes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation
by Seeger, John D and Bykov, Katsiaryna and Bartels, Dorothee B and Huybrechts, Krista and Zint, Kristina and Schneeweiss, Sebastian
Thrombosis and Haemostasis, ISSN 0340-6245, 2015, Volume 113, Issue 6, pp. 1277 - 1289
Summary The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for stroke prevention in non-valvular atrial fibrillation. It... 
Stroke, Systemic or Venous Thromboembolism | Warfarin | Cohort study | Dabigatran | TRIALS | DESIGN | cohort study | EVENTS | RISK | PERIPHERAL VASCULAR DISEASE | NEWLY MARKETED MEDICATIONS | ADJUSTMENT | HEMATOLOGY | PROPENSITY SCORES | warfarin | Dabigatran - adverse effects | Myocardial Infarction - epidemiology | Follow-Up Studies | Humans | Middle Aged | Drug Evaluation | Hospitalization - statistics & numerical data | Warfarin - adverse effects | Male | Dabigatran - therapeutic use | Thrombophilia - etiology | Warfarin - therapeutic use | Insurance Coverage | Young Adult | Polypharmacy | Aged, 80 and over | Adult | Female | Retrospective Studies | Embolism - etiology | Embolism - epidemiology | Thrombophilia - drug therapy | Databases, Factual | Brain Ischemia - epidemiology | Cerebral Hemorrhage - chemically induced | Stroke - prevention & control | Comorbidity | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Brain Ischemia - etiology | Anticoagulants - adverse effects | Atrial Fibrillation - blood | Propensity Score | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Cerebral Hemorrhage - epidemiology | Factor Xa Inhibitors - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text P286Safety and effectiveness of dabigatran relative to warfarin in routine care: final results from a long-term monitoring program
by Gopalakrishnan, C and Huybrechts, K F and Ortiz, A S and Zint, K and Gurusamy, V K and Bartels, D B and Schneeweiss, S
European Heart Journal, ISSN 0195-668X, 08/2018, Volume 39, Issue suppl_1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text PCV16 MANAGEMENT OF GASTROINTESTINAL AND UROGENITAL BLEEDING EVENTS IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION TREATED WITH DABIGATRAN ETEXILATE EARLY AFTER APPROVAL
by Riou França, L and Petrini, M and Zint, K
Value in Health, ISSN 1098-3015, 05/2019, Volume 22, pp. S121 - S121
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
by Huisman, Menno V., MD, PhD and Lip, Gregory Y.H., MD and Diener, Hans C., MD, PhD and Dubner, Sergio J., MD and Halperin, Jonathan L., MD and Ma, Chang S., MD and Rothman, Kenneth J., PhD and Teutsch, Christine, MD and Zint, Kristina, PhD and Ackermann, Diana, PhD and Clemens, Andreas, MD and Bartels, Dorothee B., PhD
American Heart Journal, ISSN 0002-8703, 2014, Volume 167, Issue 3, pp. 329 - 334
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting 1% to 2% of the population and raising the risk of stroke 5-fold. Until... 
Cardiovascular | EURO HEART SURVEY | LIFETIME RISK | CARDIAC & CARDIOVASCULAR SYSTEMS | STROKE PREVENTION | WARFARIN | Stroke - prevention & control | Cross-Sectional Studies | Atrial Fibrillation - drug therapy | Antithrombins - therapeutic use | Humans | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Treatment Outcome | Dabigatran | Stroke - etiology | Fibrinolytic Agents - therapeutic use | Registries | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Cohort Studies | Care and treatment | Anticoagulants (Medicine) | Drug approval | Atrial fibrillation | Cardiac arrhythmia | Anticoagulants | Stroke | Drug therapy | Mortality | Older people
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Evaluating utilization patterns of oral anticoagulants in routine care
by Gopalakrishnan, Chandrasekar and Schneeweiss, Sebastian and Bartels, Dorothee B and Zint, Kristina and Santiago Ortiz, Adrian and Huybrechts, Krista F
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 07/2019, Volume 17, Issue 7, pp. 1033 - 1043
Essentials Unlike warfarin, treatment with DOACs do not require regular plasma level monitoring. We compared persistence of patients treated with DOACs... 
dabigatran | persistence | rivaroxaban | utilization | apixaban | SAFETY | COMPLETENESS | ADHERENCE | DISCONTINUATION | THERAPY | WARFARIN | PERIPHERAL VASCULAR DISEASE | NEWLY MARKETED MEDICATIONS | HEMATOLOGY | Rivaroxaban | Evaluation | Atrial fibrillation | Analysis | Apixaban
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran
by Zint, Kristina and Kreuzer, Jörg
JAMA Internal Medicine, ISSN 2168-6106, 07/2015, Volume 175, Issue 7, pp. 1244 - 1244
MEDICINE, GENERAL & INTERNAL | ATRIAL-FIBRILLATION | Atrial Fibrillation - drug therapy | Antithrombins - adverse effects | Humans | Warfarin - adverse effects | Female | Male | Hemorrhage - chemically induced | Anticoagulants - adverse effects | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
by Mazurek, Michał and Huisman, Menno V and Rothman, Kenneth J and Paquette, Miney and Teutsch, Christine and Diener, Hans-Christoph and Dubner, Sergio J and Halperin, Jonathan L and Ma, Chang Sheng and Zint, Kristina and Elsaesser, Amelie and Lu, Shihai and Lip, Gregory Y. H and GLORIA-AF Investigators and on behalf of the GLORIA-AF Investigators
Thrombosis and Haemostasis, ISSN 0340-6245, 12/2017, Volume 117, Issue 12, pp. 2376 - 2388
Abstract Introduction  Although guideline-adherent antithrombotic therapy (ATT) for stroke prevention in atrial fibrillation (AF) is associated with lower... 
Stroke, Systemic or Venous Thromboembolism | regional differences | atrial fibrillation | GLORIA-AF | stroke prevention | anticoagulation | IMPROVED OUTCOMES | MANAGEMENT | CHADS-VASC SCORE | ANTAGONIST ORAL ANTICOAGULANTS | HIGH-RISK PATIENTS | ESC GUIDELINES | WARFARIN | CATHETER ABLATION | EURO HEART SURVEY | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Latin America - epidemiology | Japan - epidemiology | Prospective Studies | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Europe - epidemiology | Risk | Treatment Outcome | China - epidemiology | Thromboembolism - epidemiology | Drug-Related Side Effects and Adverse Reactions - epidemiology | Fibrinolytic Agents - adverse effects | Atrial Fibrillation - epidemiology | Fibrinolytic Agents - therapeutic use | Registries | Aged | North America - epidemiology | Practice Guidelines as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Jean Cocteau and André Gide: an abrasive friendship
by Peters, Arthur King, 1919-2001 and Cocteau, Jean, 1889-1963 and Gide, André, 1869-1951
1973, ISBN 9780813507095, xv, 426
Gide, André, 1869-1951 | Cocteau, Jean, 1889-1963
Book
Details down arrow
14. Full Text Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program
by Mazurek, Michał and Huisman, Menno V and Rothman, Kenneth J and Paquette, Miney and Teutsch, Christine and Diener, Hans-Christoph and Dubner, Sergio J and Halperin, Jonathan L and Zint, Kristina and França, Lionel Riou and Lu, Shihai and Lip, Gregory Y.H and GLORIA-AF Investigators
The American Journal of Medicine, ISSN 0002-9343, 08/2018, Volume 131, Issue 8, pp. 945 - 955.e3
Data on gender differences in oral anticoagulation for stroke prevention in patients with atrial fibrillation are conflicting, largely limited to regional... 
GLORIA-AF | Oral anticoagulation | Gender | Atrial fibrillation | MANAGEMENT | CHADS-VASC SCORE | MEDICINE, GENERAL & INTERNAL | THERAPY | STROKE RISK-FACTOR | ESC GUIDELINES | EURO HEART SURVEY | SEX-DIFFERENCES | ISCHEMIC-STROKE | FOCUSED UPDATE | Stroke - prevention & control | Risk Assessment | Atrial Fibrillation - therapy | Humans | Middle Aged | Risk Factors | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Male | Fibrinolytic Agents - therapeutic use | Sex Factors | Female | Registries | Aged | Atrial Fibrillation - diagnosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records
by Huybrechts, Krista F and Gopalakrishnan, Chandrasekar and